US FDA nod for Roche’s VENTANA ALK (D5F3) CDx assay as companion diagnostic for NSCLC… EP News Bureau Mar 9, 2021 The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments
Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC EP News Bureau Mar 4, 2021 Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA…
